Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial ...Middle East

NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that its lead asset, IMU-838, the...

Hence then, the article about immunic inc announces that oral treatment imu 838 shows evidence of clinical activity in moderate covid 19 in phase 2 calvid 1 trial was published today ( Wednesday 17/02/2021 - 03:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial )

Also on site :

• Trump posts boastful Atlas-inspired Truth Social image of himself carrying the world on his shoulders
• SoftBank’s CEO isn’t the only one with questions about Elon Musk’s orbital data center hype
• Donald Trump Compares Young Photo of Himself to Teenage Barack Obama